Braun Stacey Associates Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 80.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,494 shares of the company’s stock after selling 101,873 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Johnson & Johnson were worth $3,797,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. GW&K Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $35,000. Dark Forest Capital Management LP lifted its stake in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares during the period. Ruedi Wealth Management Inc. purchased a new stake in Johnson & Johnson in the fourth quarter worth $42,000. Kepos Capital LP purchased a new stake in Johnson & Johnson in the fourth quarter worth $45,000. Finally, VitalStone Financial LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth $52,000. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Price Performance
NYSE JNJ opened at $172.92 on Wednesday. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The stock has a 50-day moving average of $165.50 and a 200 day moving average of $161.20. The company has a market capitalization of $449.41 billion, a price-to-earnings ratio of 35.00, a PEG ratio of 2.92 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.59 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- 3 Fintech Stocks With Good 2021 Prospects
- On Holding Slips Into A More Comfortable Price PointÂ
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Growing Cannabis Stocks Ready To Bloom
- How to Invest in Lithium and Lithium Stocks
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
